Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc. (RXDX) Stock Overview

Explore Prometheus Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

RXDX●NASDAQ
HealthcareBiotechnology
$199.92
$0.18(0.09%)
U.S. Market is Open · 14:10

Prometheus Biosciences, Inc. (RXDX)

Meyka AI Score

Z

Key Financials

Market Cap9.6B
P/E Ratio-57.28
EPS (TTM)$-3.54
ROE-0.31%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$356.60

RXDX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Prometheus Biosciences, Inc. (NASDAQ: RXDX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Prometheus Biosciences, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RXDX on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $356.60 for the NASDAQ listing.

Key metrics behind Prometheus Biosciences, Inc.'s NASDAQ-traded stock include a P/E ratio of -57.28 and a market capitalization of 9.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RXDX on the NASDAQ.

Price Performance (NASDAQ: RXDX)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
75.35%
6-Month Change
64.88%
Year-to-Date (YTD) Change
87.54%
1-Year Change
576.55%
3-Year Change
690.51%
5-Year Change
690.51%
All-Time (Max) Change
690.51%

Contact Information

https://www.prometheusbiosciences.com
858 684 1300
9410 Carroll Park Drive, San Diego, CA, 92121

Company Facts

970 Employees
IPO DateMar 12, 2021
CountryUS

Frequently Asked Questions